Immatics N.V. (FRA:4A3)

Germany flag Germany · Delayed Price · Currency is EUR
10.07
+0.07 (0.70%)
At close: Dec 5, 2025
33.11%
Market Cap 1.24B
Revenue (ttm) 84.76M
Net Income (ttm) -119.99M
Shares Out n/a
EPS (ttm) -0.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 775
Open 10.07
Previous Close 10.00
Day's Range 10.07 - 10.07
52-Week Range 3.08 - 10.07
Beta n/a
RSI 62.23
Earnings Date Nov 21, 2025

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Harpreet Singh
Employees 682
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4A3
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.